Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$15.08 USD
-0.22 (-1.44%)
Updated Oct 2, 2024 09:52 AM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Income Statements
Fiscal Year end for Pacira BioSciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 675 | 667 | 542 | 430 | 421 |
Cost Of Goods | 185 | 199 | 140 | 117 | 107 |
Gross Profit | 490 | 468 | 401 | 312 | 314 |
Selling & Adminstrative & Depr. & Amort Expenses | 403 | 408 | 311 | 266 | 304 |
Income After Depreciation & Amortization | 88 | 60 | 90 | 46 | 10 |
Non-Operating Income | -6 | -7 | -2 | -1 | 2 |
Interest Expense | 20 | 40 | 32 | 26 | 24 |
Pretax Income | 62 | 13 | 56 | 20 | -11 |
Income Taxes | 20 | -3 | 14 | -125 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 42 | 16 | 42 | 146 | -11 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 42 | 16 | 42 | 146 | -11 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 167 | 159 | 144 | 87 | 46 |
Depreciation & Amortization (Cash Flow) | 79 | 99 | 54 | 40 | 35 |
Income After Depreciation & Amortization | 88 | 60 | 90 | 46 | 10 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 51.98 | 46.54 | 45.63 | 43.68 | 41.51 |
Diluted EPS Before Non-Recurring Items | 2.09 | 1.84 | 2.26 | 1.30 | 0.86 |
Diluted Net EPS (GAAP) | 0.89 | 0.34 | 0.92 | 3.33 | -0.27 |
Fiscal Year end for Pacira BioSciences, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 178.02 | 167.12 | 181.24 | 163.93 | 169.47 |
Cost Of Goods | 44.26 | 47.42 | 47.69 | 39.75 | 48.21 |
Gross Profit | 133.76 | 119.70 | 133.55 | 124.18 | 121.26 |
SG&A, R&D, and Dept/Amort Expenses | 105.52 | 106.49 | 100.38 | 106.45 | 81.38 |
Income After SG&A, R&D, and Dept/Amort Expenses | 28.24 | 13.21 | 33.17 | 17.73 | 39.88 |
Non-Operating Income | 12.23 | 3.74 | 3.94 | 2.34 | 1.84 |
Interest Expense | 3.88 | 3.32 | 3.39 | 3.46 | 3.87 |
Pretax Income | 36.58 | 13.64 | 33.72 | 16.60 | 37.85 |
Income Taxes | 17.70 | 4.66 | 8.85 | 5.74 | 12.09 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 18.89 | 8.98 | 24.87 | 10.86 | 25.76 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 18.89 | 8.98 | 24.87 | 10.86 | 25.76 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 50.54 | 52.19 | 52.06 | 52.07 | 52.05 |
Diluted EPS Before Non-Recurring Items | 0.64 | 0.42 | 0.71 | 0.52 | 0.61 |
Diluted Net EPS (GAAP) | 0.39 | 0.19 | 0.58 | 0.23 | 0.51 |